Volume 3.43 | Nov 9

Prostate Cell News 3.43 November 9, 2012
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Notch and TGFβ Form a Reciprocal Positive Regulatory Loop that Suppresses Murine Prostate Basal Stem/Progenitor Cell Activity
Researchers found that Notch ligands are mainly expressed within the basal cell lineage, while active Notch signaling is detected in both the prostate basal and luminal cell lineages. [Cell Stem Cell] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by impact factor of the journal)


The Enzymatic Activity of Apoptosis Inducing Factor Supports Energy Metabolism Benefitting the Growth and Invasiveness of Advanced Prostate Cancer Cells
Researchers explored the contribution of apoptosis inducing factor (AIF) to the progression of prostate cancer. Analysis of archival gene expression data demonstrated that AIF transcript levels are elevated in human prostate cancer, and the researchers found that AIF protein is increased in prostate tumors. [J Biol Chem] Abstract

P21-Activated Kinase 6 (PAK6) Inhibits Prostate Cancer Growth via Phosphorylation of Androgen Receptor and Tumorigenic E3 Ligase Murine Double Minute-2 (Mdm2)
Regulation of androgen receptor (AR) homeostasis in prostate tumorigenesis has not yet been fully characterized. Investigators demonstrated that p21-activated kinase 6 inhibits prostate tumorigenesis by regulating AR homeostasis. [J Biol Chem] Abstract

Genetic Ablation of the Tetraspanin Cd151 Reduces Spontaneous Metastatic Spread of Prostate Cancer in the TRAMP Model
Scientists showed that genetic ablation of CD151 inhibits spontaneous metastasis in a transgenic mouse model of de novo tumorigenesis. To evaluate the effects of CD151 on de novo prostate cancer initiation and metastasis, a Cd151-/- murine model was crossed with the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model. [Mol Cancer Res] Abstract

Polymorphisms in Thioredoxin Reductase and Selenoprotein K Genes and Selenium Status Modulate Risk of Prostate Cancer
Researchers assessed whether risk of prostate cancer is affected by genetic variants in genes coding for selenoproteins, either alone or in combination with Selenium status. [PLoS One] Full Article

Midkine Is Associated with Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Expression of growth factor midkine (MDK) is correlated with poor clinical outcomes in various human cancers, including prostate cancer (PC). Scientists evaluated MDK expression and neuroendocrine differentiation in two separate tumor groups: early and advanced PC. [Prostate] Abstract

PCA3 Noncoding RNA Is Involved in the Control of Prostate-Cancer Cell Survival and Modulates Androgen Receptor Signaling
To investigate putative function of PCA3 in prostate cancer biology, investigators used gene expression knockdown by small interference RNA and also analyzed its involvement in androgen receptor signaling. [BMC Cancer] Abstract | Full Article

Association of Legumain Expression Pattern with Prostate Cancer Invasiveness and Aggressiveness
Researchers investigated the clinical implication of legumain, an asparaginyl endopeptidase that is highly expressed in several types of cancer, expression in prostate cancer. [World J Urol] Abstract | Full Article


Selenoprotein P Genetic Variants and mRNA Expression, Circulating Selenium, and Prostate Cancer Risk and Survival
Researchers utilized a nested case-control study of 1,352 prostate cancer cases and 1,382 controls. They assessed four single nucleotide polymorphisms capturing common variation within the selenoprotein P (SEPP1) locus. In a subset of men, they evaluated SEPP1 mRNA expression in tumors. [Prostate] Abstract

HOXB13 Mutations in a Population-Based, Case-Control Study of Prostate Cancer
Investigators determined the distribution and frequency of the G84E HOXB13 variant in 1,310 incipient prostate cancer (PC) cases and 1,259 age-mated controls from a population-based, case-control study of PC. [Prostate] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.

Modeling Prostate Cancer in Mice: Something Old, Something New, Something Premalignant, Something Metastatic
This review describes genetically engineered mouse models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future. [Cancer Metastasis Rev] Abstract
New Targeted Therapy for Advanced Prostate Cancer Shows Anti-Tumor Activity in Phase I Clinical Trials
Researchers reported that a new drug that specifically targets a protein found on the surface of prostate cancer cells has performed well in a phase I clinical trial, and a phase II trial has started. The drug reduced levels of circulating tumor cells and levels of prostate specific antigen, a marker for tumor activity, in patients who had already failed previous chemotherapy and hormone treatments. [Press release from AlphaGalileo Foundation discussing research presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin] Press Release

Presentations at Leading Radiation Oncology Meeting Highlight Cyberknife Prostate Outcomes from Patients at More Than 40 Centers
Accuray Incorporated announced clinical findings using non-invasive CyberKnife® stereotactic body radiation therapy for the treatment of prostate cancer. [Press release from Accuray Inc. discussing research presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting, Boston] Press Release

OncoGenex Announces Completion of Patient Enrollment in Custirsen Phase III “SYNERGY” Study
OncoGenex Pharmaceuticals, Inc. announced the completion of patient enrollment in the primary registration phase III study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer. [PR Newswire Association LLC] Press Release

£20 Million Investment for UK Synthetic Biology Research
In a move that could potentially revolutionize major UK industries and help us to meet serious social and environmental challenges, the Biotechnology and Biological Sciences Research Council has announced an unprecedented £20M worth of synthetic biology projects. [Biotechnology and Biological Sciences Research Council] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Target Meeting’s 2nd World Cancer Online Conference
January 8-11, 2013

our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Postdoctoral Position – Prostate Cancer Metastasis (Lund University)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Position – Molecular Mechanisms of Advanced Prostate Cancer (UT Southwestern Medical Center)

Research Manager (Prostate Cancer UK)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Translational Program in Endocrine-Related Cancers (Baylor College of Medicine)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us